Relay Therapeutics (NASDAQ:RLAY) disclosed transactions by Chief Financial Officer Thomas Catinazzo that included a multi-price sale of common stock and a separate option exercise with an immediate sale. According to a Form 4 filing with the Securities and Exchange Commission, Catinazzo sold 17,717 shares of Relay Therapeutics common stock on April 7, 2026, at prices between $12.42 and $13.46, for proceeds totaling $257,498.
The filing also reports that on April 9, 2026, Catinazzo exercised stock options to acquire 1,800 shares at an exercise price of $5.22. Those shares were then sold at $15.00, generating $27,000 in proceeds. The Form 4 indicates that the transactions were carried out under a pre-arranged Rule 10b5-1 trading plan that Catinazzo adopted on October 30, 2025.
Following the reported activity, Catinazzo retains direct ownership of 213,867 shares of Relay Therapeutics common stock, which includes 13,075 shares that are associated with restricted stock units. In addition, the filing shows he directly holds 61,563 shares in stock options.
Market context noted in the filing and accompanying commentary places Relay Therapeutics shares near a 52-week high of $15.00, a level that reflects approximately a 576% gain over the prior 12 months. Despite the price run-up, InvestingPro analysis characterizes the stock as appearing overvalued at current levels. An InvestingPro tip within available materials further highlights that Relay Therapeutics carries more cash than debt on its balance sheet, with more detailed analysis offered in the company’s Pro Research Report.
Separately, Relay Therapeutics released Phase 1/2 trial data for zovegalisib, administered in combination with fulvestrant, in patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer. The trial evaluated a 400 mg twice-daily dose taken with food and produced a reported progression-free survival of 11.1 months, as noted by Oppenheimer.
Following the disclosure of those trial results, several equity research firms updated their views. Oppenheimer reiterated an Outperform rating and maintained a $14 price target. H.C. Wainwright increased its price target to $19 and kept a Buy rating. Raymond James reiterated a Strong Buy rating with a $19 target, citing Novartis’s acquisition of a competing drug candidate. Guggenheim raised its price target to $22, pointing to a vascular malformations opportunity and projecting significant sales potential for zovegalisib. These analyst actions reflect heightened attention to the company’s clinical progress and commercial prospects within oncology.
The Form 4 filing, the option exercise details, the ownership position, the InvestingPro valuation view, and the clinical data and subsequent analyst notes compose the public record of recent developments for Relay Therapeutics that investors and market participants can review.